EN DE
Watch Laboratory Corporation of America Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Laboratory Corporation of America Holdings (LH) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of Laboratory Corporation of America Holdings stock $231, price $368, that is 37.2% below the price, quality 69 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LC Laboratory Corporation of America Holdings logo Broad data Nov 6, 2026

Laboratory Corporation of America Holdings

LH · US
Solid, but very expensive

Our calculation puts a fair price 37% below what the stock costs today.

Quality 69/100
Healthy Growth (revenue YoY +7.2 %/yr in USD)
Generates free cash flow
0.8% dividend yield · Well covered
Ranks above peers (10/14)
Positive coverage
Broad data
Thin margins · 6.9% net margin (TTM)
Moderate debt
Moderate moat 49/100 · thin data
Insiders sold $5.4M (6M)
Fair value $230.82 · Strongly overvalued (−37.2%)

Risks from the AI analysis

🚩Proposed Medicare cuts pressuring core diagnostics🚩DTC platforms and startups pressuring routine testing🚩False Claims Act scrutiny on test billing
Watch Laboratory Corporation of America Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$368.16 $167.37 Fair Value $230.82 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $167.37 – $368.16 · fair‑value band $127.61 – $296.84 · the $367.79 price screens above the $230.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Laboratory Corporation of America in your weekly email

Every Wednesday you see whether Laboratory Corporation of America is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services.

Show moreShow less

The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.

It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations.

In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool.

It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics.

It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North

Stock analysis

Laboratory Corporation of America Holdings (LH) currently trades at $367.79, while our model-based Fair Value estimate is $230.82, 37% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $235.27 per share, and 0 of the 24 models we run sit above the $367.79 price.

Bear case: the Dividend Discount group reads lowest at $48.50, and 24 of the 24 models stay below the price. Data coverage for this calculation is high.

Scenario range: $127.61 (bear) to $296.84 (bull), the price of $367.79 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Laboratory Corporation of America Holdings reported revenue of $14.0B in FY2025 versus $13.1B in FY2021, a compound +1.5%/yr. Reported net income was $877M in FY2025, compounding −22.1%/yr from FY2021.

Key figures

Market cap $30.2B Large · P/E ratio 30.1 · P/S ratio 2.07 · EPS (TTM) $12.20 · Dividend yield 0.8% · Net margin 6.9% · Return on equity 11.4% · Return on assets (EBIT) 8.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades at its 52-week high and 51% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −37%, LH screens richer than that median.

Fair Value models

Bear $127.61 Fair Value $230.82 Bull $296.84
Price $367.79 · Downside -37.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($7.92 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $148.62 $277.82 $484.52 77
Growth DCF $150.99 $262.87 $429.36 76
Residual Income $94.45 $105.18 $137.07 76
All 24 models by family
DCF Models
FCF DCF $148.62 $277.82 $484.52 77
Owner Earnings $59.34 $132.18 $248.72 72
5Y Revenue Exit $121.42 $230.82 $372.02 70
5Y EBITDA Exit $182.22 $347.65 $544.63 73
5Y P/E Exit $119.07 $226.30 $340.72 69
10Y Revenue Exit $123.72 $227.68 $371.29 65
10Y EBITDA Exit $168.53 $310.46 $507.15 66
10Y P/E Exit $127.61 $224.48 $346.65 62
Earnings-Based
Graham-Dodd $73.40 $258.58 $347.90 64
Lynch FV $60.45 $86.35 $112.26 61
PEG = 1.0 $60.45 $86.35 $112.26 57
EPV $96.64 $122.45 $145.12 74
Dividend Discount
Gordon GGM $27.53 $57.91 $93.11 66
DDM Multi-Stage $27.53 $48.50 $60.68 66
Multiples
P/E Multiple $178.11 $237.48 $296.84 63
P/S Multiple $137.63 $183.50 $229.38 58
EV/EBIT $155.91 $235.27 $314.63 65
EV/EBITDA $201.97 $296.68 $391.39 66
EV/Revenue $87.76 $160.58 $233.40 52
Growth DCF
Growth DCF $150.99 $262.87 $429.36 76
Rev-Margin DCF $121.42 $230.59 $360.56 71
Economic Profit
Residual Income $94.45 $105.18 $137.07 76
ROIC Compounder $96.64 $134.53 $191.88 71
Growth Earnings
Growth-Adj P/E $153.12 $218.74 $284.36 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 69/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 42
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 62
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 76
How calm the share price moves, does not count
Price momentum 75
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 91
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 7 officers or directors sold shares worth $5.4M and none bought.

  • SaleRichelle P ParhamDirector1,078 shares at $361.22$389,395Oct 30, 2026
  • SaleKerrii B AndersonDirector3,000 shares at $318.02$954,060Aug 17, 202610b5-1 plan
  • SaleAdam H SchechterPresident & CEO, Director5× since Nov 11, 2025: 30,295 shares, avg. $278.73$8.4MAug 11, 2026
  • SaleAmy B. SummyEVP, Chief Marketing Officer924 shares at $306.74$283,428Aug 4, 2026
  • SalePeter J WilkinsonSVP, Chief Accounting Officer3× since Feb 19, 2026: 3,719 shares, avg. $285.11$1.1MAug 3, 2026
  • SaleBryan T VaughnEVP and President, Diagnostics234 shares at $286.19$66,968Jul 2, 202610b5-1 plan
  • SaleKathryn W KyleEVP, Chief Legal Officer2× since Jun 8, 2026: 854 shares, avg. $266.29$227,414Jul 2, 202610b5-1 plan
  • SaleJonathan C MeltzerEVP, Operations4× since Feb 9, 2026: 1,105 shares, avg. $270.37$298,756Mar 27, 202610b5-1 plan
  • SaleSandra D van der VaartEVP, Corporate Affairs548 shares at $284.91$156,000Feb 27, 2026
  • SaleBrian J CaveneyEVP, Pres of ED, CMO & CSO1,500 shares at $286.31$429,465Feb 24, 2026

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 4, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 74/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+7.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.0%
Dividend (yield on the price)0.8%
Per share before 2023divided by the spin-off factor 1.164
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.2% vs 7.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.6% a year for the price and +2.5% for the forecasts.
Forecast 2026 (sales)+6.2%
Forecast 2027 (sales)+5.2%
Projected 2028 (sales)+4.8%
Projected 2029 (sales)+4.4%
Projected 2030 (sales)+4.0%

LH screens overvalued: fair value 37% below the price. Compare with Thermo Fisher Scientific Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Labcorp draws moderate strength from diagnostic scale that backs its long-term revenue targets, yet thin evidence leaves its ability to offset core pressures unconfirmed.
Main risk: Direct-to-consumer platforms and startups such as Function Health or Hims & Hers could offer lower-priced or subscription-based lab tests often fulfilled via major labs, squeezing margins or shifting volume in Labcorp's routine diagnostics segment.
Bull case: Labcorp could leverage its scale, biopharma expansion and AI tools like Test Finder to strengthen specialty testing and integrated offerings that differentiate it from lower-cost DTC alternatives.
Bear case: If DTC models and billing scrutiny intensify, routine diagnostics could face sustained price pressure and compliance burdens, limiting growth in Labcorp's core business despite specialty efforts.
Labcorp is reaffirming its 5-8% annual revenue growth target through 2029 while expanding its biopharma lab network via the MLM acquisition for global clinical trial support. At the same time proposed Medicare reimbursement cuts add pressure to the core diagnostics business. Will specialty testing and efficiency gains fully offset any diagnostics headwinds?
Join the discussion →

Compare Laboratory Corporation of America Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 69 · Top 25%
Fair Value upside −37.2% · Below median
Profitability
Return on equity (12 months) 11.4% · Above median
Return on assets 4.8% · Above median
Net margin (12 months) 6.9% · Above median
Operating margin (12 months) 11.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 6.9% · Below median
Dividend yield (12 months) 0.8% · Below median
Balance sheet
Debt / equity 0.59× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 30.1× · Cheaper than median
P/B 3.50× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.07× · Cheaper than median
Price / free cash flow 25.0× · Cheaper than median
EV/EBITDA 14.8× · Cheaper than median
PEG 1.40× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)35 · sector 38
PAST (return on equity)46 · sector 15
HEALTH (low debt)71 · sector 95
DIVIDEND (yield)16 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $226.54 $262.03 +16% vs LH
IQVIA Holdings IQV $263.79 $288.85 +10% vs LH
WuXi AppTec Co 603259 ¥154.46 ¥164.66 +7% vs LH
Thermo Fisher Scientific Inc TMO $706.16 $686.04 −3% vs LH
Danaher Corporation DHR $234.93 $209.18 −11% vs LH
IDEXX Laboratories, Inc IDXX $698.55 $496.48 −29% vs LH
Mettler-Toledo International Inc MTD $1,723 $648.30 −62% vs LH
Agilent Technologies, Inc A $177.17 $64.53 −64% vs LH
Lonza Group LONN CHF 672.40 CHF 153.50 −77% vs LH
Waters Corporation WAT $467.60 $91.26 −80% vs LH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Laboratory Corporation of America Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Laboratory Corporation of America Holdings Fair Value". https://www.fairvalue-calculator.com/stock/LH

Frequently asked questions

Is Laboratory Corporation of America Holdings (LH) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $230.82 versus a price of $367.79, about 37% lower (overvalued).
What is the fair value of LH?
Our model-based fair value for Laboratory Corporation of America Holdings is $230.82 (as of Nov 6, 2026), built from audited fundamentals. The current price: $367.79.
What is the quality score of LH?
Laboratory Corporation of America Holdings has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Laboratory Corporation of America Holdings (LH)?
Our model-based price target is the fair value of $230.82 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $127.61, optimistic scenario $296.84. It is a calculation from audited fundamentals, not an analyst target.
What is the Laboratory Corporation of America Holdings stock forecast for 2026?
Our models put fair value at $230.82, about 37% lower versus a price of $367.79 (overvalued). Cautious scenario $127.61, optimistic scenario $296.84. The calculation is refreshed regularly with new filings.
What is the revenue of Laboratory Corporation of America Holdings (LH)?
Laboratory Corporation of America Holdings reported trailing-twelve-month revenue of about $14.6B (latest available figure, as of Nov 6, 2026).
Does Laboratory Corporation of America Holdings pay a dividend?
Laboratory Corporation of America Holdings currently shows a dividend yield of 0.78% relative to its recent price (as of Nov 6, 2026).
What growth is priced into Laboratory Corporation of America Holdings (LH)?
For today's price to be fair in a discounted-cash-flow model, Laboratory Corporation of America Holdings would have to grow free cash flow by +14.2 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 0.0 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of LH use?
Our models discount Laboratory Corporation of America Holdings at 8.9 %: a base by market capitalisation (large), damped by beta 0.85, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Laboratory Corporation of America Holdings that is +14.2 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Laboratory Corporation of America Holdings (LH) delivered so far?
Over the past 5 years revenue at Laboratory Corporation of America Holdings grew 0.0 % a year. The price currently implies +14.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Laboratory Corporation of America Holdings (LH) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Laboratory Corporation of America Holdings (+14.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Laboratory Corporation of America Holdings (LH)?
The free-cash-flow yield on the price is 4.00 %: that much free cash flow Laboratory Corporation of America Holdings produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Laboratory Corporation of America Holdings (LH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Laboratory Corporation of America Holdings it is $230.82 per share (as of Nov 6, 2026), against a price of $367.79. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Laboratory Corporation of America Holdings stock overvalued or undervalued in 2026?
As of Nov 6, 2026, LH trades above its calculated fair value: price $367.79, fair value $230.82, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LH?
No. The price is what the market pays today ($367.79); the fair value is what the company's own numbers justify ($230.82). For Laboratory Corporation of America Holdings the two are $136.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Laboratory Corporation of America Holdings worth?
The market values Laboratory Corporation of America Holdings at about $30.2B (market capitalisation, as of Nov 6, 2026). Per share that is $367.79; our models calculate a fair value of $230.82 per share.
What do the bullish and bearish scenarios say about LH?
Our models span a range for Laboratory Corporation of America Holdings: cautious scenario $127.61, base $230.82, optimistic $296.84 per share (as of Nov 6, 2026, price $367.79). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LH?
Laboratory Corporation of America Holdings trades at a price-to-earnings ratio of 30.1 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $230.82 is built from several models across several years. Other multiples: PEG 1.4, P/B 3.5, P/S 2.1, EV/EBITDA 14.8.
What is the PEG ratio of LH?
The PEG ratio of Laboratory Corporation of America Holdings is 1.40 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Laboratory Corporation of America Holdings (LH)?
Balance-sheet figures for Laboratory Corporation of America Holdings (as of Nov 6, 2026): return on equity 11.4%, debt of 0.59 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is LH from its 52-week high?
Laboratory Corporation of America Holdings trades at $367.79, at its 52-week high of $368.16 and 51% above the low of $244.17 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $230.82 is for.
Which stocks are comparable to Laboratory Corporation of America Holdings?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Laboratory Corporation of America Holdings stock attractive at the current price?
The data as of Nov 6, 2026: price $367.79, calculated fair value $230.82 (−37%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LH calculated?
We run Laboratory Corporation of America Holdings through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $230.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Laboratory Corporation of America Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Laboratory Corporation of America Holdings (LH)?
The closing price on Nov 4, 2026 was $367.79. Our model-based fair value is $230.82, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Laboratory Corporation of America Holdings right now?
The price sits above even our optimistic bull case ($296.84). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($127.61 to $296.84) leaves room in how you read the outcome.
Where does the earnings growth of Laboratory Corporation of America Holdings (LH) come from?
Earnings per share at Laboratory Corporation of America Holdings grew +3.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.0 %, EBIT margin −4.8 %, tax rate +2.1 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Laboratory Corporation of America Holdings

How large is the market capitalisation of Laboratory Corporation of America Holdings (LH)?
The market capitalisation of Laboratory Corporation of America Holdings is $30.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Laboratory Corporation of America Holdings (LH)?
The price-to-sales ratio of Laboratory Corporation of America Holdings is 2.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Laboratory Corporation of America Holdings (LH)?
Earnings per share at Laboratory Corporation of America Holdings are $12.20 (price ÷ EPS = P/E 30.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Laboratory Corporation of America Holdings (LH)?
The dividend yield of Laboratory Corporation of America Holdings is 0.8% (payout 23.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Laboratory Corporation of America Holdings (LH)?
The net margin of Laboratory Corporation of America Holdings is 6.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Laboratory Corporation of America Holdings (LH)?
The return on equity (ROE) of Laboratory Corporation of America Holdings is 11.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Laboratory Corporation of America Holdings (LH)?
On an EBIT basis the return on assets of Laboratory Corporation of America Holdings is 8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Laboratory Corporation of America Holdings (LH)?
The operating margin of Laboratory Corporation of America Holdings is 11.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Laboratory Corporation of America Holdings (LH)?
Revenue at Laboratory Corporation of America Holdings is growing +6.9% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Laboratory Corporation of America Holdings (LH)?
Earnings per share at Laboratory Corporation of America Holdings are growing +3.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Laboratory Corporation of America Holdings (LH) carry?
The net debt of Laboratory Corporation of America Holdings is $6.7B (fiscal year 2025, ≈ 5.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Laboratory Corporation of America Holdings in the live analysis

One click puts Laboratory Corporation of America Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.